

① J7193	Factor ix (antihemophilic factor, purified, non-recombinant) per i.u. <i>AlphaNine SD, Mononine</i>	K K2	② J7295	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each Medicare Statute 1862(a)(1) AHA: 4Q 2021, 7	E I
① J7194	Factor ix, complex, per i.u. <i>Bebulin, Konyne 80, Profilnine SD, Proplex T</i>	K K2	③ J7296	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg Cross reference Q9984 <i>Kyleena</i> Medicare Statute 1862(a)(1)	♀ E I
① J7195	Injection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified <i>Aprolix, BeneFix, Idelvion, IXINITY</i>	K K2	④ J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg <i>Liletta</i> Medicare Statute 1862(a)(1) AHA: 1Q 2016, 8	♀ E I
■ J7196	Injection, antithrombin recombinant, 50 i.u. <i>ATryn</i> AHA: 1Q 2011, 6	E2 K5	⑤ J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg <i>Mirena</i> Medicare Statute 1862(a)(1) AHA: 1Q 2016, 8	♀ E I
① J7197	Antithrombin iii (human), per i.u. <i>Thrombate III</i>	K K2	⑥ J7300	Intrauterine copper contraceptive <i>ParaGard, Paragarel T380A</i> Medicare Statute 1862A1	E I
① J7198	Anti-inhibitor, per i.u. <i>Autoplex T, FEIBA</i> NCD 110.3	K K2	⑦ J7301	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg <i>Skyla</i> Medicare Statute 1862(a)(1)	♀ E I
① J7199	Hemophilia clotting factor, not otherwise classified NCD 110.3 AHA: 2Q 2013, 5	B	⑧ J7304	Contraceptive supply, hormone containing patch, each Medicare Statute 1862.1	E I
① J7200	Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu <i>Rixubis</i>	K K2	⑨ J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies <i>Kyleena</i>	E I
① J7201	Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u. <i>Alprolix</i>	K K2			
① J7202	Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u. <i>Idelvion</i> AHA: 4Q 2016, 9	K K2			
① J7203	Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (Rebinyn), 1 iu <i>Rebinyn</i> AHA: 1Q 2019, 8	K K2			
■ J7204	Injection, factor viii, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei, per iu <i>Esperoct</i>	G K2			
① J7205	Injection, factor viii fc fusion protein (recombinant), per iu <i>Eloctate</i> AHA: 1Q 2016, 6	K K2			
① J7207	Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u. <i>Adynovate, Jivi</i>	K K2			
① J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-auci, (Jivi), 1 i.u. AHA: 3Q 2019, 5	K K2			
■ J7209	Injection, factor viii, (antihemophilic factor, recombinant), (Nuwiq), 1 i.u. <i>Nuwig</i>	K K2	⑩ J7307	Etonogestrel (contraceptive) implant system, including implant and supplies <i>Nexplanon</i>	E I
■ J7210	Injection, factor viii, (antihemophilic factor, recombinant), (Afystyla), 1 i.u. <i>Afystyla</i>	K K2	■ J7308	Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg) <i>Levulan Kerastick</i>	K K2
■ J7211	Injection, factor viii, (antihemophilic factor, recombinant), (Kovaltry), 1 i.u. <i>Kovaltry</i>	K K2	⑪ J7309	Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram <i>Metvixia</i> AHA: 1Q 2011, 6	E2 K5
■ J7212	Factor viia (antihemophilic factor, recombinant)- jncw (sevenfact), 1 microgram <i>Sevenfact</i> AHA: 1Q 2021, 6	G K2	⑫ J7310	Ganciclovir, 4.5 mg, long-acting implant <i>Vitrasert</i>	E2 K5
② J7294	Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each Medicare Statute 1862(a)(1) AHA: 4Q 2021, 7	E I	■ J7311	Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg <i>Retisert</i>	K K2
			■ J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	K K2

### Insertion of implantable contraceptive capsules

